Acadia Pharmaceuticals Inc
Research Acadia Pharmaceuticals Inc (ACAD) on Bullrun: market cap USD 5.26B, P/E 13.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACAD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.26B
- P/E13.8
- Financial periodQ2 2026
- RevenueUSD 307.96M
- Net incomeUSD 31.50M
- Free cash flowUSD 95.69M
- Gross margin90.8%
Valuation Snapshot
latest market cap is USD 5.26B; P/E is 13.8.
Peer valuation comparison
Latest P/E is 13.77x versus a Healthcare sector median of 24.46x (43.7% below).
Latest P/E is 13.77x versus a United States median of 24.87x (44.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.07B | USD 391.00M | USD 105.15M | 91.7% | 2.3 | USD 177.70M | USD 52.19M | USD 1.23B |
| FY2024 | USD 957.80M | USD 226.00M | USD 157.20M | 91.5% | 1.36 | USD 319.59M | USD 52.00M | USD 732.79M |
| FY2023 | USD 726.44M | -USD 61.00M | USD 16.65M | 94.3% | -0.37 | USD 188.66M | USD 57.21M | USD 431.76M |
| FY2022 | USD 517.24M | -USD 214.00M | -USD 114.04M | 98.0% | -1.34 | USD 114.85M | USD 53.77M | USD 400.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.26B | 13.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.55B | 11.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.06B | 13.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.14B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.58B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.76B | n/a | n/a | n/a |
About Acadia Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Acadia Pharmaceuticals Inc's market cap?
Acadia Pharmaceuticals Inc's market capitalization is USD 5.26B.
What is Acadia Pharmaceuticals Inc's P/E ratio?
Acadia Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 13.8.
What does Acadia Pharmaceuticals Inc do?
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.